Pegylated Liposomal Doxorubicin in Salvage Chemotherapy for Multiple Myeloma Patients

Author(s): Alessandra Romano, Giuseppina Uccello, Paolo Spina, Rosario Cunsolo, Calogero Vetro, Francesco Di Raimondo

Journal Name: Current Cancer Therapy Reviews

Volume 9 , Issue 1 , 2013

Become EABM
Become Reviewer
Call for Editor


Anthracyclines show anti myeloma effects, being part of active regimens like infusional vincristine/ doxorubicin/ pulsed dexamethasone (VAD) in the past and recently of bortezomib/doxorubicin/pulsed dexamethasone (PAD) for the treatment of multiple myeloma. The recent introduction of pegylated liposomal doxorubicin has led to the development of newer anthracycline-containing regimens with improved toxicity profiles.

In vitro, anthracyclines are able of suppressing bortezomib-mediated induction of some stress response proteins with a large synergic effect. Clinical trials have shown impressive activity of pegylated liposomal doxorubicin and conventional doxorubicin in combination with bortezomib in patients with relapsed/refractory myeloma. Herein, we review the clinical data supporting the use of pegylated liposomal doxorubicin combined to active agents in salvage regimens for relapsed/ refractory multiple myeloma patients.

Keywords: Multiple myeloma, relapse, doxorubicin, salvage chemotherapy.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Published on: 04 February, 2013
Page: [1 - 7]
Pages: 7
DOI: 10.2174/1573394711309010001

Article Metrics

PDF: 16